Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study (Q46648883)

23 December 2017

title

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study (English)

1 reference

23 December 2017

0 references

1 reference

1 reference

1 reference

1

Jason D Wright

1 reference

23 December 2017

Keiichi Fujiwara

6

object named as

Keiichi Fujiwara

1 reference

23 December 2017

author name string

Chunqiao Tian

2

1 reference

23 December 2017

David G Mutch

3

1 reference

23 December 2017

Thomas J Herzog

4

1 reference

23 December 2017

Shoji Nagao

5

1 reference

23 December 2017

Matthew A Powell

7

1 reference

23 December 2017

language of work or name

English

0 references

publication date

14 April 2008

1 reference

23 December 2017

published in

Gynecologic Oncology

1 reference

23 December 2017

volume

109

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

353-358

1 reference

23 December 2017

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Clinical pharmacokinetics and dose optimisation of carboplatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Effect of obesity on survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Association of obesity and ovarian cancer in a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Undertreatment of obese women receiving breast cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Formula-based dosing for carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Renal function--estimation of glomerular filtration rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

Clinical Pharmacokinetics of Carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.023

10.1016/J.YGYNO.2008.02.023

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017